Ischemic heart disease and cerebrovascular disease are the leading causes of death in the
world. Surprisingly, these diseases are treated by relatively antiquated drugs. However, due …

As a pathological coagulation process, thrombus can lead to many serious diseases,
including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

Abstract Background Milvexian (BMS‐986177/JNJ‐70033093) is an orally bioavailable
factor XIa (FXIa) inhibitor currently in phase 2 clinical trials. Objectives To evaluate in vitro …

Modification of a series of pyrazole factor Xa inhibitors to incorporate an
aminobenzisoxazole as the P1 ligand resulted in compounds with improved selectivity for …

Abstract BMS-262084 is a 4-carboxy-2-azetidinone-containing irreversible inhibitor of FXIa,
which is selective over other coagulation proteases. We evaluated the in vitro and in vivo …

As part of an ongoing effort to prepare orally active factor Xa inhibitors using structure-based
drug design techniques and molecular recognition principles, a systematic study has been …

Factor Xa, a serine protease, is at the critical juncture between the intrinsic and extrinsic
pathways of the coagulation cascade. Inhibition of factor Xa has the potential to provide …

Abstract BMS-654457 ((+) 3′-(6-carbamimidoyl-4-methyl-4-phenyl-1, 2, 3, 4-tetrahydro-
quinolin-2-yl)-4-carbamoyl-5′-(3-methyl-butyrylamino)-biphenyl-2-carboxylic acid) is a …

Adenosine diphosphate directly induces platelet aggregation via the G-protein coupled P2Y
1 and P2Y 12 receptors. P2Y 12, but not P2Y 1, receptor antagonists are available in the …